Our Law Firm has advised Kvarko sp. z o.o. on its investment in Biovetika sp. z o.o.
Our Law Firm has advised the Kvarko fund on its investment in Biovetika sp. z o.o., which carries out the project entitled “Innovative technology in the production of LPS vaccines against Gram-negative bacteria”. Total funds acquired by Biovetika sp. z o.o. amounted to PLN 1 million.
The fund was represented by Jarosław Rudy, Partner and Advisor at our Law Firm.
The purpose of the “Innovative technology in the production of LPS vaccines against Gram-negative bacteria” project carried out by Biovetika sp. z o.o. was to develop a method of production of veterinary vaccines against bacteria whose cell membrane contains bacterial lipopolysaccharide (LPS), called endotoxin. The vaccines, which are to be used for breeding animals (poultry, pigs), will compete with whole cell anti-microbial vaccines that are already available in the market and are considered by veterinary surgeons as ineffective or poorly effective. The application of the new vaccines could reduce the rate of infection of poultry and pigs with Gram-negative bacteria.
The project is carried out on the basis of the experience and achievements of scientific staff of the Institute of Immunology and Experimental Therapy of the Polish Academy of Science in Wrocław.
related posts
Can the contribution of shares in the form of a contribution in kind be treated as a disposal of shares benefiting from the CIT exemption for income of alternative investment companies (in Poland called: “ASI”)?
Can the contribution of shares in the form of a contribution in kind be treated as a disposal of shares benefiting from the CIT exemption for income of alternative investment companies (in Poland called: “ASI”)?Income of a Polish family foundation from its participation in a Luxembourg-based Societe en commandite speciale (“SCSp”) vs. CIT exemption.
Income of a Polish family foundation from its participation in a Luxembourg-based Societe en commandite speciale (“SCSp”) vs. CIT exemption.